News coverage about GlaxoSmithKline (NYSE:GSK) has been trending somewhat positive recently, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. GlaxoSmithKline earned a news impact score of 0.13 on Accern’s scale. Accern also assigned media headlines about the pharmaceutical company an impact score of 46.2260151718314 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media headlines that may have effected Accern Sentiment’s analysis:
- Take a look at GlaxoSmithKline plc (GSK) EPS surprise while stock price is now worth at $40.15 (topdesertsafari.com)
- Bifunctional Epoxide Hydrolase 2 Market Top Vendors 2018 – GlaxoSmithKline Plc, Sphaera Pharma Pvt. Ltd … (digitaljournal.com)
- Hot Stocks to Observe: Texas Instruments Incorporated (NASDAQ:TXN), GlaxoSmithKline plc (NYSE:GSK), Workhorse … (journalfinance.net)
- GlaxoSmithKline plc (GSK)- Investors are Unsure How to React (Brief Analysis) (topdesertsafari.com)
- The No. 1 Reason To Buy VeriFone Systems, Inc. (PAY), GlaxoSmithKline plc (GSK) (gvtimes.com)
Shares of GSK opened at $39.80 on Wednesday. The company has a market cap of $99.57 billion, a PE ratio of 13.82, a PEG ratio of 1.98 and a beta of 0.84. GlaxoSmithKline has a 1 year low of $34.52 and a 1 year high of $42.36. The company has a debt-to-equity ratio of 8.13, a quick ratio of 0.61 and a current ratio of 0.94.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 11th. Stockholders of record on Friday, August 10th will be issued a dividend of $0.496 per share. The ex-dividend date is Thursday, August 9th. This represents a $1.98 annualized dividend and a dividend yield of 4.98%. GlaxoSmithKline’s dividend payout ratio (DPR) is 68.75%.
GSK has been the topic of a number of research analyst reports. Zacks Investment Research raised GlaxoSmithKline from a “sell” rating to a “hold” rating in a report on Tuesday, July 17th. Shore Capital raised GlaxoSmithKline from a “hold” rating to a “buy” rating in a report on Friday, July 27th. DZ Bank reissued a “buy” rating on shares of GlaxoSmithKline in a report on Thursday, June 14th. Bank of America set a $40.00 price target on GlaxoSmithKline and gave the stock a “hold” rating in a report on Wednesday, July 25th. Finally, ValuEngine cut GlaxoSmithKline from a “hold” rating to a “sell” rating in a report on Friday, May 4th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and six have assigned a buy rating to the company. GlaxoSmithKline currently has an average rating of “Hold” and an average price target of $40.17.
In other news, major shareholder Plc Glaxosmithkline acquired 80,000 shares of the firm’s stock in a transaction dated Tuesday, July 17th. The shares were acquired at an average cost of $12.50 per share, with a total value of $1,000,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders have bought a total of 498,048 shares of company stock worth $6,136,988 over the last ninety days. Insiders own 10.00% of the company’s stock.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Further Reading: What does relative strength index mean?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.